Spironolactone Shortage Alert (Canada)

Due to a national shortage of spironolactone, healthcare providers across Canada are actively adjusting treatment plans to ensure patient safety and equitable access. The shortage affects all marketed forms of spironolactone, including JAMP, Mint, Aldactone, and Teva brands. A guidance document was developed collaboratively by the Canadian Pharmacists Association (CPhA) and the Canadian Society of Hospital Pharmacists (CSHP), with input from the Canadian Cardiovascular Society and the Canadian Heart Failure Society (CHFS) for managing cardiovascular conditions.

What You Need to Know:

· Spironolactone is a widely used medication for treating cardiovascular and hormonal conditions, including heart failure, hypertension, cirrhosis, and hypokalemia. It is also prescribed off-label for acne, hirsutism, gender-affirming care, and seborrheic dermatitis.

· Patients currently prescribed spironolactone should not stop taking it without consulting their healthcare provider.

· Alternatives like eplerenone or amiloride may be considered depending on the condition.

· Stockpiling is discouraged—please refill only a 30-day supply at a time.

We encourage patients to speak with their healthcare providers about treatment options and to stay informed through http://www.drugshortagescanada.ca/.

We will continue to update you on this important issue as we learn more.

If you have any questions or concerns related to the ongoing aminophylline shortage, please contact communications@ccs.ca.